MPO

MPO
Name	Myeloperoxidase
Uniprot	P05164
Location	Neutrophil, Monocyte
Function	Heme-dependent peroxidase activity
Molecular mass	~150 kDa (dimer)

MPO Myeloperoxidase is a heme-containing peroxidase enzyme abundant in azurophilic granules of Neutrophil, and present in Monocyte and some Macrophage populations. First characterized in studies of leukocyte granules and oxidative host defense, MPO catalyzes formation of reactive halogen species from hydrogen peroxide and halide substrates, contributing to microbial killing during Innate immunity responses and influencing inflammatory processes implicated in Atherosclerosis and other pathologies. MPO has been studied in contexts ranging from infectious diseases to cardiovascular risk assessment and autoimmune disorders such as Vasculitis.

Definition and nomenclature

MPO is commonly referred to by its gene symbol MPO and by historical names including "leukocyte peroxidase" and "azurophil peroxidase" in early hematology literature. The MPO gene was mapped and annotated alongside other immune-related loci in analyses involving Chromosome 17 (human), linking genetic variation to enzyme expression differences observed in cohorts studied by investigators at institutions like NIH and research consortia including the Human Genome Project. Nomenclature in protein databases aligns with entries maintained by groups such as UniProt and classification schemes used by the International Union of Biochemistry and Molecular Biology.

Structure and biochemical properties

MPO is synthesized as a precursor polypeptide that undergoes proteolytic processing and dimerization to yield a mature heterotetramer composed of two heavy and two light chains coordinated around two covalently bound heme prosthetic groups; structural details were resolved by X-ray crystallography performed in laboratories associated with Brookhaven National Laboratory and structural biology centers at Harvard University and European Molecular Biology Laboratory. The active site contains an iron-containing heme that forms compound I intermediates during catalysis, a mechanism described in comparisons with other peroxidases such as Horseradish peroxidase and Lactoperoxidase. MPO displays strong absorbance in the Soret region characteristic of heme proteins; mass spectrometry studies by groups at Max Planck Institute contributed to mapping of heavy chain glycosylation sites that influence stability and plasma clearance. Biochemically, MPO oxidizes chloride, bromide, and thiocyanate to produce hypochlorous acid, hypobromous acid, and hypothiocyanite respectively, with reaction rates modulated by pH and availability of hydrogen peroxide generated by enzymes such as NADPH oxidase.

Biological function and mechanism of action

MPO contributes to microbicidal activity within phagosomes by using hydrogen peroxide produced by NADPH oxidase complexes to convert halides into highly reactive oxidants that damage microbial proteins, lipids, and nucleic acids; electron paramagnetic resonance and imaging studies at centers like University of Oxford have visualized MPO-derived oxidants in inflamed tissues. Beyond direct antimicrobial effects, MPO-derived oxidants modify host biomolecules, promoting formation of chlorinated tyrosine residues and oxidation of low-density lipoprotein particles—findings advanced by research groups at Johns Hopkins University and Columbia University linking MPO activity to oxidative modifications implicated in Atherosclerosis plaque progression. MPO also interacts with extracellular traps released by Neutrophil activation, a process investigated in studies from Yale University and Karolinska Institutet, influencing thrombosis and tissue injury in models of Sepsis and ischemia-reperfusion.

Clinical significance and medical applications

Elevated MPO levels and activity have been associated with increased risk of cardiovascular events in epidemiological studies conducted by cohorts such as Framingham Heart Study and clinical series from Mayo Clinic; MPO is investigated as a biomarker for acute coronary syndromes and prognosis after Myocardial infarction. Pathogenic roles have been documented in autoimmune vasculitides where anti-neutrophil cytoplasmic antibodies characterized in research at University College London target neutrophil components leading to MPO-associated disease phenotypes. MPO inhibitors have been explored in preclinical studies and early-phase trials at biotechnology firms and academic centers including Novartis and University of California, San Francisco as potential therapies for inflammatory and cardiovascular conditions. Conversely, MPO deficiency, first described in hematology reports from Stanford University, can predispose to atypical infections in selected patients and alter outcomes in chronic inflammatory disorders. Diagnostic histochemistry using diaminobenzidine and immunohistochemistry with monoclonal antibodies developed in laboratories at Abbott Laboratories remains standard for identifying MPO activity and distribution in tissue specimens.

Measurement and laboratory testing

Laboratory assessment of MPO includes immunoassays for plasma MPO concentration, activity assays measuring chlorination or oxidation of reporter substrates, and mass spectrometric quantification of specific MPO-derived modification products such as 3-chlorotyrosine; commercial immunoassays were validated in multicenter studies involving clinical laboratories accredited by College of American Pathologists. Flow cytometry protocols for intracellular MPO staining assist hematopathology diagnostics in settings like World Health Organization classification of leukemias. Standardization of assays is complicated by preanalytical variables, anticoagulant choice, and analytic interferences documented in method comparison studies from clinical chemistry groups at Cleveland Clinic.

Genetic and regulatory aspects

The human MPO gene locus contains regulatory elements responsive to transcription factors studied in cell biology work at Massachusetts Institute of Technology and Rockefeller University, with promoter polymorphisms such as the −463G/A variant associated with altered promoter activity and disease susceptibility in genetic association studies performed by consortia including the International HapMap Project. Epigenetic regulation, including DNA methylation patterns reported in cohorts analyzed by teams at University of Cambridge and microRNA-mediated post-transcriptional control described in research at Scripps Research Institute, modulates MPO expression in myeloid differentiation and during inflammatory responses. Knockout and transgenic mouse models developed at institutions like The Jackson Laboratory have been instrumental in dissecting MPO’s roles in host defense and chronic disease models.

Category:Enzymes